Pharmacokinetic Considerations in Gastrointestinal Motor Disorders
- 1 January 1995
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 28 (1) , 41-66
- https://doi.org/10.2165/00003088-199528010-00005
Abstract
Although it has been recognised that alterations in gastrointestinal motility, whether induced by physiological or pathological processes, have significant effects on the pharmacokinetics of orally administered drugs, this subject has received inappropriately little attention. Studies relating to this topic have focused on healthy volunteers and animals and have largely been confined to the effects of single drug doses. There is limited information about the effects of disease on pharmacokinetics under steady-state conditions. Changes in gastrointestinal motility may affect the pharmacokinetics of orally administered drugs by altering the rate of delivery, bioavailability or mucosal absorption of the drug. In general the rate of absorption and time taken to achieve maximal plasma concentrations for well absorbed drugs may be modified by changes in gastrointestinal motility, but overall bioavailability is not usually affected. In these cases the therapeutic and clinical effects of the alteration in pharmacokinetics will, therefore, depend on which parameters are important for the action of the drug. For poorly absorbed drugs both the rate of absorption and bioavailability are likely to be altered by changes in gastrointestinal motility However, the complex effects of food and disease, as well as the properties and formulation of any drug (solubility, ease of dispersion, delayed release formulation) often make the prediction of the magnitude, or even the direction, of any effect difficult to predict. Drugs with direct effects on gastrointestinal motility may influence their own patterns of absorption. In patients with gastrointestinal motility disorders, drugs administered in a controlled release formulation, or those with poor bioavailability, are most likely to have a poorly predictable therapeutic effect. Care should be taken to ensure that the formulation of the drug, its timing of administration in relation to meals and the use of coadministered drugs optimise, or at least ensure consistent absorption.Keywords
This publication has 96 references indexed in Scilit:
- Diabetic GastroparesisDrugs, 1992
- Cigarette smoking and nicotine delay postprandial mouth-cecum transit timeDigestive Diseases and Sciences, 1992
- Effect of verapamil on human intestinal transitDigestive Diseases and Sciences, 1992
- Gastric Emptying Rate of Drug Preparations. III. Effects of Size of Enteric Micro-Capsules with Mean Diameters Ranging from 0.1 to 1.1mm in Man.CHEMICAL & PHARMACEUTICAL BULLETIN, 1992
- Effects of Cisapride on Gastrointestinal Motor Activity and Gastric Emptying of Disopyramide.Journal of Pharmacobio-Dynamics, 1992
- Effects of verapamil and diltiazem on gastric emptying in normal subjectsDigestive Diseases and Sciences, 1991
- Gastric emptying of indigestible tablets in relation to composition and time of ingestion of meals studied by metal detectorDigestive Diseases and Sciences, 1991
- Opposite effects of metoclopramide and propantheline on intestinal absorption of imipramine in rats.Journal of Pharmacobio-Dynamics, 1991
- Improvement of Gastric Emptying in Diabetic Gastroparesis by ErythromycinNew England Journal of Medicine, 1990
- Drugs, Diseases and Altered Gastric EmptyingClinical Pharmacokinetics, 1976